Navigation Links
Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

SOUTH SAN FRANCISCO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George Scangos, Ph.D., the company's president and chief executive officer, will present at the 26th Annual JPMorgan Healthcare Conference at 7:30 a.m. PT / 10:30 p.m. ET on Thursday, January 10, 2008.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... EU Citizens (6%) Have Liver Diseases, 5th Most Common Cause of ... ... Abuse Takes 13,000,Number With Fatty Liver Disease Stable or Growing; Viral Hepatitis Declines, ... world gathered today in this historic Italian,city to attend the opening sessions of ...
... one for analyzing tumors , Doctors treating individuals with ... oxygen in a tumor very useful, because low levels of oxygen ... new method to do this and to image the surrounding organs ... to image tumors in mice by Murali Krishna and colleagues, at ...
... the biggest-selling,biologics developed during the boom years in biotech ... have lost patent,protection in the U.S. in 2007 or ... This opens up a huge potential market for biosimilars, ... report by Kalorama,Information, Biogenerics: the World Market for Biosimilars., ...
Cached Biology Technology:Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 2Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 3JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:9/18/2014)... to undertake jaunts into the countryside each year could come ... century, according to new research. , Climate change could postpone ... as summer temperatures linger later into the year, Princeton University ... . For instance, the paper birch a popular foliage ... could change color one to three weeks later by the ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
(Date:9/18/2014)... The tropical rabbitfish which have devastated algal forests in ... the entire Mediterranean basin if their distribution continues to ... The study, by an international team of researchers led ... Fiona Tomas of the Mediterranean Institute for Advanced Studies ... Ecology ., Members of the team surveyed more than ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... has landed a University of Central Florida scientist more ... could have profound benefits in the search for cures ... Annette Khaled is conducting research into what triggers the ... surrounding cells. If its secrets could be unlocked and ...
... Contaminated seaweeds in Sydney Harbour could be threatening the small ... revealing that the harbour,s seaweeds have the world,s highest levels ... of the offspring of small crustaceans that feed on a ... exposed to copper at levels found in some parts of ...
... early diagnosis of Alzheimers, Parkinsons and other diseases has ... Jersey Technology Council competition. Based at NJITs business ... , a start-up company, was named most likely to ... entrepreneurs and investors. NeuroTrax develops ...
Cached Biology News:'Death protein' research secures funding for UCF scientists 2Sydney harbors deadly diet for sea creatures 2NJIT start-up company NeuroTrax named best in show 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... are designed for ultra-sensitive detection of ... PVDF membranes. Since all necessary reagents ... antibodies), the WesternBreeze Kits save you ... and getting your final results. Solutions ...
Biology Products: